The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary HEPTAD platform.
The HEPTAD platform generates potential novel antibodies against difficult-to-drug protein targets in immunology, and has specific capabilities which target transmembrane protein targets, complementing AbbVie’s current robust capabilities in biotherapeutics research.
